

1 **Impact of the COVID-19 pandemic on the uptake of intermittent sulphadoxine-pyrimethamine for**
2 **prevention of malaria amongst pregnant women in Sierra Leone**

3 William Tilima Pessima¹, Bailah Molleh², Musa Silla-Kanu¹, Brenda Stafford¹, Wani Kumba Lahai¹,
4 Dr Abdul Mac Falama¹, Sharmistha Mishra³, Adrienne K. Chan³, Stephen Sevalie,^{2,4} Sulaiman
5 Lakoh,^{1,2} Michael Lahai^{5,6}

6 **Affiliations:**

7 ¹ National Malaria Control Programme, Ministry of Health, Freetown, Sierra Leone

8 ² Sustainable Health Systems, Freetown, Sierra Leone

9 ³ Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, University of
10 Toronto, Toronto, Canada

11 ⁴ 34 Military Hospital, Wilberforce, Freetown, Sierra Leone

12 ⁵ Faculty of Pharmaceutical Sciences, University of Sierra Leone, Freetown, Sierra Leone

13 ⁶ Pharmacy Board of Sierra Leone, Government of Sierra Leone, Freetown, Sierra Leone

14

15 Short title: Impact of COVID-19 on malaria prevention in pregnant women in Sierra Leone

16 Corresponding author: Sulaiman Lakoh (lakoh2009@gmail.com, +23278287492)

17

18

19

20

21 **Abstract**

22 **Background:** Malaria in pregnancy contributes to high maternal mortality, warranting the adoption
23 of intermittent preventive treatment (IPTp) of malaria in pregnancy in Sierra Leone in 2017. Since
24 then, the uptake of IPTp has increased but it is unclear whether COVID-19 has any impact on these
25 services. We aimed to assess the impact of COVID-19 on the uptake of IPTp among pregnant
26 women in Sierra Leone at district, regional, and national levels.

27 **Methods:** A retrospective cross-sectional study design was used to assess the monthly aggregated
28 data from DHIS2 for all 5 regions of Sierra Leone. We describe the trends of IPTp1, IPTp2, and
29 IPTp3+ uptake at national, regional, and district levels before, during and after COVID-19. Data was
30 analysed using STATA. The median and interquartile range for each outcome in each period were
31 calculated.

32 **Results:** The median monthly uptake of total IPTp was the lowest before COVID (53,244) but
33 increased during COVID-19 (55,257) and after COVID-19 (59,439). IPTp1 uptake was lowest during
34 COVID-19 (20,338) but highest after COVID-19 (20,914). All three variables (IPTp1, IPTp2 and
35 IPTp3) showed a clear decline in uptake in early 2020 and recovered within 3 months in a similar
36 pattern of magnitude, except in Eastern Sierra Leone. Both IPTp2 and IPTp3 showed more
37 pronounced increases in uptake after recovery than IPTp1 and they both experienced sustained
38 increases in the post-COVID-19 period.

39 **Conclusion:** The negative impact of the COVID-19 pandemic in reducing IPTp uptake was followed
40 by rapid recovery, underscoring the resilience of the Sierra Leone's health system in response to
41 public health emergencies. However, the delay in recovery in the IPTp uptake in the Eastern Sierra

- 42 Leone highlight the need for strong differentiated regional strategies in protecting essential health
- 43 services during public health emergencies.
- 44 **Keywords:** IPTp, Malaria in pregnancy, COVID-19, Sierra Leone, Sulphadoxine-pyrimethamine

46 Introduction

47 Malaria is responsible for 822,000 children with low birth weight in sub-Saharan Africa, more than
48 half of which occur in the West African region (1) . About 6% of malaria deaths in sub-Saharan
49 Africa are due to low birth weight (2). Historically, low birth weight has been a major problem in
50 Sierra Leone, caused mostly by infections such as malaria (3). Malaria in pregnancy is associated
51 with a range of complications, including low birth weight, maternal hypoglycemia, intrauterine
52 growth retardation, placental malaria, fetal hypotrophy, miscarriage, abortion, anaemia and
53 preterm delivery, which explains the contribution of malaria to higher maternal and neonatal
54 mortality rates (4). A meta-analysis of studies primarily from sub-Saharan Africa showed that
55 successful implementation of malaria and other interventions could reduce the risk of anaemia
56 and child mortality (5).

57 Intermittent Preventive Treatment for malaria in pregnancy (IPTp) with Sulfadoxine-
58 Pyrimethamine (SP) is an evidence-based programmatic intervention that can prevent the adverse
59 outcomes of malaria in pregnancy (1). Strong programmatic efforts by national and international
60 agencies, supported by political commitment, are needed to achieve substantial progress in the
61 uptake of IPTp-SP and, in turn, reduce the prevalence of malaria in pregnancy (6). Over the past
62 decade, most sub-Saharan African countries, including Sierra Leone, have introduced IPTp policies
63 for pregnant women. The current policy of the Sierra Leone malaria programme is to administer
64 IPTp-SP at 13 weeks of gestation since 2017 and every four weeks thereafter. Similar policies had
65 been implemented in other African countries (7) (8). Similar policies had been implemented in
66 other African countries (7) (8).

67 In 2020, the early phase of the COVID-19 pandemic resulted in health system adjustments with
68 the need for reallocation of the already limited resources away from the national malaria control
69 of resources to support surveillance and other healthcare services. Concerns about the association
70 of COVID-19 with hospitals or hospital visits and the closure of some health facilities to provide
71 services to COVID-19 patients, have changed people’s health-seeking behaviour and are among
72 the barriers to access services including, IPTp-SP (9). These events led to disruptions in hospital
73 care and significantly affected access to IPTp-uptake for pregnant women in Sierra Leone. Several
74 previous studies on IPTp uptake have focused on the prevalence and predictors of IPTp uptake
75 among pregnant women (10).

76 Existing research evaluating the uptake of IPTp in Africa and Sierra Leone was more focused on
77 the factors affecting IPTp-uptake with scarce research information on IPTp disaggregated data by
78 region and district and this was not assessed in the recent multi-cluster indicator survey in Sierra
79 Leone (11). Our study aims to assess the impact of COVID-19 on the uptake of Intermittent
80 Preventive Therapy (IPTp) for malaria in pregnancy in Sierra Leone at the district, regional, and
81 national levels to inform national policy around the resiliency of the malaria control programming.

82 **Methods**

83 *Study Design*

84 We conducted a retrospective cross-sectional study using monthly aggregated secondary data on
85 IPTp uptake among pregnant women who access ANC services in their 2nd and 3rd trimester of
86 pregnancy extracted from the District Health Information system-2 (DHIS2) platform for all the 5
87 regions of Sierra Leone.

88

89 *Study Setting*

90 The health system is divided into three tiers: primary health care and extended community health
91 programs, secondary health care, and tertiary health care. The primary healthcare system has
92 1430 peripheral health units (PHUs). IPTp is given to pregnant women during routine ANC in PHUs
93 and by community health workers. The current national IPTp policy for IPTp recommends giving
94 SP at 13 weeks of pregnancy with subsequent doses every 4 weeks. We used data on IPTp uptake
95 among pregnant women from all 5 regions in Sierra Leone: Eastern (Kailahun, Kenema, and Kono
96 districts), Western Area (Urban and Rural), Northern (Bombali, Falaba, Koinadugu, and Tonkolili
97 districts), Northwest (Kambia, Karene, and Port Loko districts), and the Southern region (Bo,
98 Bonthe, Moyamba, and Pujehun districts).

99 *Data Sources and Variables*

100 Aggregated monthly data on IPTp uptake was extracted from the DHIS-2 platform, a national
101 health information system on September 4, 2023. The data were initially collected from individual
102 patients in the PHUs, aggregated monthly, and then forwarded to the District Monitoring and
103 Evaluation Officers for review and entry into the DHIS-2 platform. Each dose is for one eligible
104 person each month. IPTp1 is the first dose of IPTp given in the 2nd or 3rd trimester, IPTp2 is the
105 second dose of IPTp given 4 weeks after the first dose, IPTp3+ is the third dose of IPTp given 4
106 weeks after the second dose, and any subsequent doses given up until delivery (including the 4th
107 to 7th doses).

108 Monthly data from January 2019-December 2023 was extracted to capture seasonal variation in
109 service utilization and to reflect IPTp uptake in three time periods: January 2019-Feb 2020 (before
110 COVID-19; March 2020-Feb 2022 (during COVID-19); March 2022- December 2022 (after COVID-

111 19). Variables extracted included: the number of pregnant women who received IPTp (IPTp1,
112 IPTp2, IPTp3+) per month in the second (gestational weeks 13 to 24) and third (gestational weeks
113 24 to delivery) trimesters for 16 districts (divided into five regions).

114 ***Data Management and Analysis***

115 The data in Excel format were cleaned, coded, and validated. Analyses and data visualization were
116 performed in STATA (version 15.1 Stata Corp LLC, College Station, TX). We describe and visualize
117 trends over time to demonstrate national and regional variation in IPTp1, IPTp2, and IPTp3+
118 uptake before, during, and after COVID-19. The median and interquartile range for each outcome
119 in each period was calculated for descriptive statistics.

120 ***Ethical consideration***

121 Ethics approval was obtained from the Sierra Leone Ethics and Scientific Review Committee
122 (SLESRC number: 019/05/2023). Since routinely aggregated data, informed consent did not apply
123 with approval for data extraction and use by the Chief Medical Officer, Ministry of Health, Sierra
124 Leone. Finally, the authors did not have access to information that could identify individual
125 participants during or after data collection.

126 **Results**

127 *Uptake of IPTp before, during and after COVID-19*

128 Data from 14 months of national IPTp uptake before COVID-19, 24 months during COVID-19, and
129 10 months after COVID-19 were extracted from the DHIS-2. The median monthly uptake of total
130 IPTp was the lowest before COVID-19 (53,244) but increased during COVID-19 (55,257). The
131 exception was the median monthly uptake of IPTp1, which was lowest during COVID-19 (20,338),
132 but highest after COVID-19 (20,914) (***Table 1***).

133

134 **Table 1. Summary of IPT uptake over three time periods in Sierra Leone**

| | Pre-COVID | | During COVID | | Post-COVID | |
|---|----------------------|------------------|----------------------|------------------|----------------------|------------------|
| | Mar 2019 to Feb 2020 | | Mar 2020 to Feb 2022 | | Mar 2022 to Dec 2022 | |
| | 12 months | | 24 months | | 10 months | |
| | Median | (IQR) | Median | (IQR) | Median | (IQR) |
| Uptake per month, National level | | | | | | |
| Total (IPTp-1, IPTp-2, IPTp-3+) | 53,244 | (52,344; 53,662) | 55,257 | (52,908; 57,236) | 59,439 | (58,670; 61,288) |
| IPTp-1 | 20,405 | (19,491; 21,280) | 20,338 | (19,330; 20,901) | 20,914 | (20,362; 21,914) |
| IPTp-2 | 17,757 | (16,943; 18,103) | 17,859 | (16,882; 18,725) | 19,758 | (18,859; 20,556) |
| IPTp-3+ | 14,597 | (13,884; 15,093) | 16,982 | (15,756; 17,861) | 18,638 | (18,513; 19,186) |

135 IPTp (intermittent preventive therapy in pregnancy), IPTp-3+ refers to the 3rd dose and beyond). IQR (inter-quartile
 136 range).

137

138

139 ***Differential uptake of IPTp1, IPTp2, and IPTp3+ before, during and after COVID-19***

140 During these three time periods, there were small fluctuations in the uptake of all forms of IPTp
 141 (total IPTp, IPTp1, IPTp2 and IPTp3+). Before COVID-19, the IPTp was stable with a decline in all
 142 forms of IPTp uptake in the last three months and the start of the COVID-19 period, specifically
 143 from January-March 2020. The uptake of all forms of IPTp recovered in the first three months of
 144 the COVID-19 period (until June 2020), with a lower magnitude decline and recovery over a couple
 145 of months before steadily increasing during late COVID-19 and after COVID-19 (**Figure 1**).

146 IPTp1 uptake is highest in all the periods, with lower IPTp2 and then IPTp3+ uptake across all
 147 periods. IPTp2 and IPTp3 both had a more marked increase in uptake following recovery than
 148 IPTp1, though all experienced sustained increase after COVID-19 (**Figure 1**).

149 ***Geographic variation in the uptake of IPTp before, during and after COVID-19 across the five***
 150 ***regions of Sierra Leone***

151 We disaggregated the data by the five regions (East, North, North-West, South, and Western Area)
152 of Sierra Leone to look for regional variation in trends. All regions had stable fluctuations through
153 all time periods and all regions had a similar decline in uptake starting in January 2020, the last
154 three months of the pre-COVID-19 period. Some regions had a sharp increase in total uptake in
155 early 2021, notably the Northern and Eastern regions and the Eastern region had a slower recovery
156 after the decline compared to the other regions (**Figure 2**).

157 Discussion

158 Using longitudinal aggregate program data, we found a dynamic pattern in the uptake of IPTp over
159 three time periods shaped by the COVID-19 pandemic in Sierra Leone. We observed small
160 fluctuations in the IPTp-SP uptake throughout the three time periods of COVID-19; a decline in
161 uptake of IPTp in the latter part of the pre-COVID-19 period with further decline during the early
162 phase of the COVID-19 pandemic; and a delay in recovery of IPTp uptake in the Eastern region
163 compared to the other four regions of Sierra Leone.

164 The fluctuations in IPTp throughout all the three time periods could be related to a number of
165 factors that include management of the supply of SP (12), issues of stock-out (13) throughout the
166 three time periods in this study, and seasonal variations of the COVID-19 cases. Despite the
167 challenges in the availability of resources, and the occasional issues of stock-out, the program was
168 able to provide a continuous supply of SP for all three IPTp types until the post-COVID-19 period.
169 This was possibly because of the increased programmatic awareness of the challenges affecting
170 the prevention of malaria in pregnancy and especially with the uptake of IPTp uptake (14). A
171 qualitative study in Uganda on the barriers to uptake of IPTp revealed that supply side chain

172 management and refusal of SP account for most of the missed IPTp doses in antenatal care and
173 suggests the need for IPTp safety reassurance among pregnant women(15).

174 Overall, the most notable finding was a very clear decline in uptake of IPTp that started in January
175 2020 that had its nadir prior to the national lockdowns in April 2020, followed by recovery by mid-
176 2020, and a further increase by early 2021 and into the post-COVID-19 period. This finding was in
177 the background of an otherwise relatively steady increase over time of uptake of IPTp across all
178 periods and was similar across all geographical regions, except the Eastern region which had a
179 slower recovery. The decline in services could have started several months before the country's
180 first case (31 March 2020) and prior to the implementation of lockdown and intercountry travel
181 restriction in April 2020. Preparation for the pandemic began in late 2019 to pre-emptively address
182 population anxiety and community fear rooted in the impact of the 2014-2016 Ebola outbreak in
183 Sierra Leone(16)(17). Government mitigations in that period included shifting resources away
184 from all ministries, departments, and agencies to address the needs of the COVID-19 preparedness
185 plan with reports suggesting possible effects on community health worker motivation, low levels
186 of essential drugs in particular at the PHU levels, and limited supply drugs for use at the facilities
187 and communities (18). A systematic review in sub-Saharan Africa confirmed that some of the
188 barriers to improving IPTp uptake are poor leadership and governance, low budgetary allocation,
189 low staff motivation, long distances and long waiting times, drug stock outs, and poor
190 management of information and supply chain. Therefore, the need for malaria control programs
191 in Africa to address the barriers to low coverage and program ineffectiveness and prioritize
192 increase in the uptake of IPTp to prevent malaria in pregnancy (19).

193 Across all periods, IPTp1 uptake was highest with lower uptake of IPTp2 and then IPTp3+ across
194 all periods with the same pattern observed amongst IPTp1, 2, and 3+ regarding the timing and
195 magnitude of decline and recovery during COVID-19. The recovery and increase IPTp uptake
196 during COVID-19 and post COVID-19 appeared to be more marked with IPTp2 and 3+ such that
197 levels converged in the post-COVID-19 period. The recovery phase of IPTp uptake showed a steady
198 increase, which was maintained post-COVID-19. This overall trend of improvement in IPTp
199 indicators, particularly of IPTp2 and IPTp3+ across the time periods, reflects some programmatic
200 resiliencies that had just started before COVID-19.

201 Of note, in October 2019, Impact Malaria, a USAID initiative(20) was launched to support the
202 treatment and prevention of malaria in pregnancy . Commencement of training for healthcare
203 workers (including community health workers) on malaria in pregnancy (IPTp uptake and other
204 related malaria services) started in October 2020. The slower recovery in the Eastern region could
205 partly be explained by the delay in rolling-out of the malaria in pregnancy initiative in this region,
206 which started in the North and Southern regions before expanding to the Eastern region. Ongoing
207 support to the Community Health Worker initiative continued throughout the study period by the
208 Global Alliance Vaccine Initiative in Kono, Karene, and Bonthe and the U.S. President’s Malaria
209 Initiative (Sierra Leone) in Kailahun, Falaba, and Pujehun (21).

210 Our study suggests the need to provide appropriate measures to address supply chain issues, and
211 safety reassurance on the use of IPTp for the prevention of malaria among pregnant women. There
212 is also the need to have a system in place at national, regional, and district levels that addresses
213 emergency preparedness and readiness in disease outbreaks using a risk management approach
214 to ensure that essential services continue uninterrupted.

215 The strength of the study is that the use of data from district-level programme information
216 collected as part of routine monitoring and evaluation from a national public system should be
217 representative of the country. Study limitations are the magnitude of data computation required,
218 and the reliance on the human element for data transfer, input, and data abstraction that could
219 impact the data in the DHIS-2 platform that was used for this analysis.

220 **Conclusion**

221 There has been progress with IPTp uptake that created some resiliency in services during the
222 COVID-19 pandemic so that incremental progress could continue. Nonetheless, a critical piece of
223 pandemic preparedness and early response should incorporate planning so that ongoing services,
224 including those at the community level, are continued without interruption. Ongoing technical
225 resource assistance through programs like Impact Malaria was an effective strategy in the medium
226 term for creating resiliency in services addressing malaria in pregnancy.

227

228 **Declaration section**

229 The authors declared no conflict of interest

230 **Acknowledgements**

231 We acknowledge the staff and members of National Malaria Control Program of the Ministry of
232 Health for providing the enabling environment to conduct this study. We thank Kristy Yiu (Unity
233 Health Toronto) for her early support in coordination of the project. Finally, we thank the staff of
234 Sustainable Health System for their support. SM is supported by a Tier 2 Canada Research Chair in
235 Mathematical Modeling and Program Science.

236 **Funding:** This study was conducted with support from the Canadian Institute of Health Research:
237 (grant number: CIHR: WI1-179883).

238 **Conflict of interest:** None to declare

239 **Author's contribution:**

240 Conceptualization and study design: WTP, ML, SL, SS

241 Data curation and validation: WTP, MSK, BS, WKL, AMF

242 Methodology and formal analysis: BM, WTP, ML, MSK, SM

243 Funding acquisition, resources, supervision: SS, SL, SM, ACK

244 Writing – original draft preparation: WTP, ML, ACK

245 Writing – review & editing: MSK, BS, WKL, AMF, SM, SS, SL

246 **Availability of data:** The dataset (<https://doi.org/10.5061/dryad.4tmpg4fmx>) is available from:
247 <https://datadryad.org/stash/dashboard>.

248

249


250 References

- 251 1. Ngaba NN, Askemdet O, Junsay JPN, Yanamala M, Patel S, Hange N, et al. The Impact of
252 Intermittent Preventive Treatment with Sulphadoxine Pyrimethamine on Pregnant Women and
253 Newborns at Bon Samaritain. *Advances in Sexual & Reproductive Health Research* [Internet].
254 2024 Jan 4 [cited 2024 Sep 29];3(1):1–12. Available from:
255 [https://www.opastpublishers.com/peer-review/the-impact-of-intermittent-preventive-](https://www.opastpublishers.com/peer-review/the-impact-of-intermittent-preventive-treatment-with-sulphadoxine-pyrimethamine-on-pregnant-women-and-newborns-at-bon-sa-6749.html)
256 [treatment-with-sulphadoxine-pyrimethamine-on-pregnant-women-and-newborns-at-bon-sa-](https://www.opastpublishers.com/peer-review/the-impact-of-intermittent-preventive-treatment-with-sulphadoxine-pyrimethamine-on-pregnant-women-and-newborns-at-bon-sa-6749.html)
257 [6749.html](https://www.opastpublishers.com/peer-review/the-impact-of-intermittent-preventive-treatment-with-sulphadoxine-pyrimethamine-on-pregnant-women-and-newborns-at-bon-sa-6749.html)
- 258 2. Guyatt HL, Snow RW. Impact of Malaria during Pregnancy on Low Birth Weight in Sub-Saharan
259 Africa. *Clin Microbiol Rev* [Internet]. 2004 Oct [cited 2024 Oct 2];17(4):760–9. Available from:
260 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC523568/>
- 261 3. Morgan HG. Placental malaria and low birthweight neonates in urban Sierra Leone. *Ann Trop*
262 *Med Parasitol*. 1994 Dec;88(6):575–80.
- 263 4. Rogerson SJ, Mwapasa V, Meshnick SR. Malaria in Pregnancy: Linking Immunity and
264 Pathogenesis to Prevention [Internet]. *Defining and Defeating the Intolerable Burden of Malaria*
265 *III: Progress and Perspectives: Supplement to Volume 77(6) of American Journal of Tropical*
266 *Medicine and Hygiene*. American Society of Tropical Medicine and Hygiene; 2007 [cited 2023
267 Mar 29]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1710/>
- 268 5. Prevalence and predictors of anemia among pregnant women in Ethiopia: Systematic review
269 and meta-analysis | PLOS ONE . [cited 2024 Sep 30]. Available from:
270 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0267005>

- 271 6. Yaya S, Uthman OA, Amouzou A, Bishwajit G. Use of Intermittent Preventive Treatment among
272 Pregnant Women in Sub-Saharan Africa: Evidence from Malaria Indicator Surveys. *Trop Med*
273 *Infect Dis* [Internet]. 2018 Feb 11 [cited 2023 Mar 29];3(1):18. Available from:
274 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136633/>
- 275 7. Kamau A, Musau M, Mwakio S, Amadi D, Nyaguara A, Bejon P, et al. Impact of Intermittent
276 Presumptive Treatment for Malaria in Pregnancy on Hospital Birth Outcomes on the Kenyan
277 Coast. *Clin Infect Dis* [Internet]. 2022 Jun 22 [cited 2024 Oct 1];76(3):e875–83. Available from:
278 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907553/>
- 279 8. Anto F, Agongo IH, Asoala V, Awini E, Oduro AR. Intermittent Preventive Treatment of Malaria
280 in Pregnancy: Assessment of the Sulfadoxine-Pyrimethamine Three-Dose Policy on Birth
281 Outcomes in Rural Northern Ghana. *Journal of Tropical Medicine* [Internet]. 2019 [cited 2024
282 Oct 1];2019(1):6712685. Available from:
283 <https://onlinelibrary.wiley.com/doi/abs/10.1155/2019/6712685>
- 284 9. Gao L, Shi Q, Liu Z, Li Z, Dong X. Impact of the COVID-19 Pandemic on Malaria Control in Africa:
285 A Preliminary Analysis. *Trop Med Infect Dis* [Internet]. 2023 Jan 16 [cited 2023 Mar 31];8(1):67.
286 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863638/>
- 287 10. Buh A, Kota K, Bishwajit G, Yaya S. Prevalence and Associated Factors of Taking Intermittent
288 Preventive Treatment in Pregnancy in Sierra Leone. *Trop Med Infect Dis* [Internet]. 2019 Feb 7
289 [cited 2023 Mar 29];4(1):32. Available from:
290 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473366/>
- 291 11. Sierra Leone - Multiple Indicator Cluster Survey 2000 [Internet]. [cited 2024 Oct 1].
292 Available from: <https://microdata.unhcr.org/index.php/catalog/421>


- 293 12. Ndu A, Mbachu C, Anitube O, Ezeoke U. Inequities in the use of sulphadoxine-
294 pyrimethamine for malaria prophylaxis during pregnancy in Nigeria. *Malawi Med J* [Internet].
295 2020 Mar [cited 2024 Oct 2];32(1):45–51. Available from:
296 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366158/>
- 297 13. Lahuerta M, Sutton R, Mansaray A, Eleeza O, Gleason B, Akinjeji A, et al. Evaluation of
298 health system readiness and coverage of intermittent preventive treatment of malaria in infants
299 (IPTi) in Kambia district to inform national scale-up in Sierra Leone. *Malar J* [Internet]. 2021 Feb
300 6 [cited 2024 Oct 2];20:74. Available from:
301 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866768/>
- 302 14. WHO-HTM-GMP-2014.4-eng.pdf. [cited 2024 Oct 2]. Available from:
303 [https://iris.who.int/bitstream/handle/10665/338350/WHO-HTM-GMP-2014.4-](https://iris.who.int/bitstream/handle/10665/338350/WHO-HTM-GMP-2014.4-eng.pdf?sequence=2)
304 [eng.pdf?sequence=2](https://iris.who.int/bitstream/handle/10665/338350/WHO-HTM-GMP-2014.4-eng.pdf?sequence=2)
- 305 15. Rassi C, Graham K, King R, Ssekitooleko J, Mufubenga P, Gudoi SS. Assessing demand-side
306 barriers to uptake of intermittent preventive treatment for malaria in pregnancy: a qualitative
307 study in two regions of Uganda. *Malaria Journal* [Internet]. 2016 Nov 4 [cited 2024 Oct
308 2];15(1):530. Available from: <https://doi.org/10.1186/s12936-016-1589-7>
- 309 16. Murray RT, Drew LB, Memmott C, Bangura YM, Maring EF. A community's experience
310 during and after the Ebola epidemic of 2014–2016 in Sierra Leone: A qualitative study. *PLoS*
311 *Negl Trop Dis* [Internet]. 2021 Feb 25 [cited 2024 Oct 2];15(2): e0009203. Available from:
312 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954283/>
- 313 17. O'Leary A, Jalloh MF, Neria Y. Fear and culture: contextualising mental health impact of the
314 2014–2016 Ebola epidemic in West Africa. *BMJ Glob Health* [Internet]. 2018 Jun 22 [cited 2024

315 Oct 2];3(3): e000924. Available from:
316 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035506/>
317 18. Bhaumik S, Moola S, Tyagi J, Nambiar D, Kakoti M. Community health workers for pandemic
318 response: a rapid evidence synthesis. *BMJ Glob Health* [Internet]. 2020 Jun 10 [cited 2024 Oct
319 2];5(6): e002769. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292038/>
320 19. Thiam S, Kimotho V, Gatonga P. Why are IPTp coverage targets so elusive in sub-Saharan
321 Africa? A systematic review of health system barriers. *Malar J* [Internet]. 2013 Oct 3 [cited 2024
322 Oct 2]; 12:353. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850646/>
323 20. *PMI_Impact_Malaria_Annual_Report_Year3.pdf* [Internet]. [cited 2024 Oct 2]. Available
324 from:
325 https://assets.speakcdn.com/assets/2594/PMI_Impact_Malaria_Annual_Report_Year3.pdf
326 21. U.S. President's Malaria Initiative: Sierra Leone Malaria Operational Plan FY 2023. Available
327 at: <https://www.pmi.gov/resources/malaria-operational-plans-mops/>. Accessed January 14,
328 2025.
329



medRxiv preprint doi: <https://doi.org/10.1101/2025.01.21.25320891>; this version posted January 22, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1: Total IPTp and IPTp 1,2 and 3+ receipt per month in Sierra Leone, over three time periods. IPTp (Intermittent Preventive Therapy).



medRxiv preprint doi: <https://doi.org/10.1101/2025.01.21.25320891>; this version posted January 22, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 2: Total IPTp (intermittent preventive therapy) during pregnancy, received per month over three time periods in the five regions in Sierra Leone.